Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

• Status: Recruiting
• Trial end date: 2022-04-27
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen

Criteria

Inclusion Criteria

• Males and females with ages between 18 and 65 years old, inclusive

• Except for obesity, otherwise healthy

• Body mass index (BMI) greater than or equal to 30.0 kg/m2 and less than or equal to 40.0 kg/m2 at screening

• Other Inclusion criteria may apply

Exclusion Criteria:

• Currently receiving treatment in another investigational device or drug study

• Women of childbearing potential

• History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion

• Other Exclusion criteria may apply